原生C-反应蛋白增加,而修改的C-反应蛋白降低了无脂蛋白E-Knockout小鼠中的动脉样硬化
Susanne B Schwedler1, Kerstin Amann, Konstanze Wernicke
1Division of Nephrology, Department of Medicine, University of Würzburg, Würzburg, Germany. Pelleas@t-online.de
Circulation
|August 10, 2005
概括
改性C反应蛋白 (mCRP) 减少了小鼠的动脉样硬化,而原生C反应蛋白 (nCRP) 则使其恶化. 这一发现澄清了关于CRP的相互矛盾的研究.
科学领域:
- 心血管研究研究心血管研究
- 免疫学 免疫学 免疫学
- 生物化学 生物化学
背景情况:
- C-反应蛋白 (CRP) 在动脉动脉生成中表现出双重作用,可能促进或保护动脉样硬化.
- 显著的CRP配置,特别是美洲原生CRP (nCRP) 和单体修饰CRP (mCRP),可能会决定这些相反的功能.
研究的目的:
- 研究nCRP和mCRP对动脉样硬化发展的体内影响.
- 为了确定CRP的配置是否影响其益风性或血管保护性质.
主要方法:
- 作为动脉样硬化体的体内模型,利用了阿波利波蛋白E-Knockout (ApoE(-/-)) 的小鼠.
- 人类nCRP和mCRP (2.5毫克/公斤每周一次) 给药8周.
- 采用免疫组织化学分析斑块组成,细胞标记物和粘附分子.
主要成果:
- 在雌性ApoE小鼠中,nCRP治疗显著增加了大动脉斑块面积 (4倍).
- 与对照组相比,mCRP治疗显著减少了斑块大小 (约50%).
- 接受mCRP治疗的小鼠表现出抗炎性互白素-10水平的增加;接受nCRP治疗的小鼠表现出较高的血管细胞粘附分子表达.
结论:
- 美基nCRP和单体mCRP对ApoE-/-) 小鼠的动脉样硬化有相反的作用.
- 这些发现有助于协调之前关于CRP在动脉动脉产生中的作用的相互矛盾的报告.
- CRP的配置是其对心血管疾病发展影响的关键决定因素.
相关概念视频
01:38Inflammation
46.6K
Overview
46.6K
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
765
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
765
01:30Coronary Artery Disease I: Introduction
1.8K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
01:26Coronary Artery Disease II: Pathophysiology
1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
01:30Atherosclerosis I: Introduction
2.5K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.5K
01:26Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741